THEBUSINESSBYTES
BUREAU
BENGALURU,
MAY 20, 2026
In a major boost to
India’s rapidly expanding biotechnology and precision medicine ecosystem,
Strand Life Sciences, a subsidiary of Reliance Industries Limited, on Tuesday
announced the launch of South Asia’s first Olink Explore HT-powered proteomics
service, significantly strengthening the region’s capabilities in large-scale
multi-omics research and advanced drug discovery.
The launch marks a
strategic leap in India’s ability to conduct integrated genomics and proteomics
research at global standards, enabling researchers and pharmaceutical companies
to generate deeper biological insights from extremely small sample volumes with
unprecedented speed and precision.
Proteomics — the
large-scale study of proteins that drive nearly every biological process in the
human body — is increasingly emerging as one of the most powerful tools in
modern medicine. By analysing how protein levels change in health and disease,
scientists can better understand disease mechanisms, identify drug targets, and
design more personalised treatment strategies.
Powered by Olink
Explore HT, the newly launched platform can measure more than 5,400 protein
biomarkers from just 2 microlitres of sample, roughly one-twenty-fifth of a
drop of blood. This enables simultaneous, high-resolution analysis of thousands
of proteins, dramatically enhancing the ability to conduct complex
translational and clinical research studies.
Strand Life Sciences
said it has already completed a major proteomics project for a biopharma
partner involving chronic kidney disease patients, demonstrating the platform’s
real-world potential in clinical and translational research.
The company noted
that the integration of proteomics with genomics, bioinformatics and clinical
datasets would allow pharmaceutical and biotechnology companies to compress
what were once lengthy sequential research processes into large-scale
integrated discovery programmes, accelerating timelines for drug development
and biomarker validation.
For clinicians and
patients alike, the implications could be transformative. Proteomics-driven
biomarkers are expected to support more accurate diagnosis, improved treatment
selection, and the advancement of precision medicine across a range of
diseases.
Dr. Ramesh Hariharan,
CEO of Strand Life Sciences, said the company was bringing one of the world’s
most advanced proteomics platforms to India and the wider region at a time when
demand for integrated multi-omics capabilities is rising rapidly worldwide.
“With Olink Explore HT, Strand is bringing one
of the world’s most advanced proteomics platforms to India and the region. By
combining this with established strengths in genomics, bioinformatics, and
clinical partnerships, Strand aims to deliver end-to-end multi-omics programmes
and enable faster, more impactful discovery,” he said, while inviting
collaborations with global pharmaceutical and biotechnology companies.
The Bengaluru-based
company said it is now positioned to support the creation of large, multi-modal
datasets across diverse populations in India, South Asia and West Asia through
its broad network of clinical partners. The platform is expected to support research
across multiple therapeutic areas including oncology, nephrology, metabolic
disorders and rare diseases.
With global
pharmaceutical companies increasingly seeking integrated biological datasets to
improve drug discovery outcomes, Strand’s early adoption of Olink Explore HT is
expected to strengthen India’s standing as an emerging hub for high-impact
biomedical research and precision healthcare innovation.
